The prognostic significance of p16 expression pattern in diffuse gliomas

CDKN2A is a tumor suppressor gene that encodes the cell cycle inhibitor protein p16. Homozygous deletion of the CDKN2A gene has been associated with shortened survival in isocitrate dehydrogenase (IDH)-mutant gliomas. This study aimed to analyze the prognostic value of p16 and to evaluate whether p1...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pathology and translational medicine 2021, 55(2), , pp.102-111
Main Authors: Park, Jin Woo, Kang, Jeongwan, Lim, Ka Young, Kim, Hyunhee, Kim, Seong-Ik, Won, Jae Kyung, Park, Chul-Kee, Park, Sung-Hye
Format: Article
Language:English
Subjects:
Brain cancer
cdkn2a
Cell cycle
Cell growth
Cloning
Dehydrogenases
Gene amplification
glioma
immunohistochemistry
Labeling
Medical prognosis
Mutation
Original
p16
prognosis
Protein expression
Proteins
Survival analysis
Tumors
병리학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CDKN2A is a tumor suppressor gene that encodes the cell cycle inhibitor protein p16. Homozygous deletion of the CDKN2A gene has been associated with shortened survival in isocitrate dehydrogenase (IDH)-mutant gliomas. This study aimed to analyze the prognostic value of p16 and to evaluate whether p16 immunohistochemical staining could be used as a prognostic marker to replace CDKN2A genotyping in diffuse gliomas. p16 immunohistochemistry was performed on tissue microarrays of 326 diffuse gliomas with diagnoses that reflected IDH-mutations and 1p/19q codeletion status. The results were divided into three groups (negative, focal expression, overexpression) according to the presence and degree of p16 expression. Survival analysis was performed to assess the prognostic value of p16 expression. A loss of p16 expression predicted a significantly worse outcome in all glioma patients (n=326, p
ISSN:2383-7837
2383-7845
DOI:10.4132/JPTM.2020.10.22